Studies on progressive muscular dystrophy. IV. Effects of original amino acids mixture on progressive muscular dystrophy.
D000255:Adenosine Triphosphate / Q000627:therapeutic use*; D000293:Adolescent; D000328:Adult; D000596:Amino Acids / Q000032:analysis* / Q000627:therapeutic use*; D001120:Arginine / Q000627:therapeutic use; D001216:Asparagine / Q000627:therapeutic use; D001224:Aspartic Acid / Q000627:therapeutic use; D001798:Blood Proteins / Q000032:analysis; D002648:Child; D003677:Deficiency Diseases / Q000188:drug therapy; D005971:Glutamates / Q000627:therapeutic use; D005998:Glycine / Q000627:therapeutic use; D006639:Histidine / Q000627:therapeutic use; D006801:Humans; D007532:Isoleucine / Q000627:therapeutic use; D007930:Leucine / Q000627:therapeutic use; D008239:Lysine / Q000627:therapeutic use; D008297:Male; D008715:Methionine / Q000627:therapeutic use; D009132:Muscles / Q000032:analysis*; D009136:Muscular Dystrophies / Q000188:drug therapy* / Q000378:metabolism; D010649:Phenylalanine / Q000627:therapeutic use; D013912:Threonine / Q000627:therapeutic use; D014364:Tryptophan / Q000627:therapeutic use; D014443:Tyrosine / Q000627:therapeutic use; D014633:Valine / Q000627:therapeutic use
D000596:Amino Acids; D001798:Blood Proteins; D005971:Glutamates; D007532:Isoleucine; D013912:Threonine; D001224:Aspartic Acid; D014443:Tyrosine; D010649:Phenylalanine; D006639:Histidine; D001216:Asparagine; D014364:Tryptophan; D000255:Adenosine Triphosphate; D001120:Arginine; D008715:Methionine; D007930:Leucine; D014633:Valine; D008239:Lysine; D005998:Glycine